
|Articles|September 26, 2007
DEA classifies oripavine as Schedule II
Oripavine is designated a Schedule II controlled substance by the Drug Enforcement Administration
Advertisement
DEA has issued a final rule designating oripavine as a basic class in Schedule II of the Controlled Substances Act. The agency explained that there's no need to promulgate this rule as a proposal first because oripavine is already subject to control under Schedule II as a derivative of thebaine, a natural constituent of opium. DEA is taking this new action in order to comply with international treaty obligations. The final rule took effect on Sept. 24. For more information on the rule, go to
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Heat and Older Adults: What Pharmacists Need to Know
5





























































